Enzian Pharmaceutics

Enzian Pharmaceutics, founded in 2016 and based in Zug, Switzerland, is innovating in the drug delivery sector with a proprietary platform for gastroretentive oral dosage forms. The company's technology utilizes a unique 3D-printed fibrous microstructure that expands in the stomach to enable prolonged, constant drug release, addressing a key limitation of conventional tablets and capsules. This approach seeks to maintain optimal drug concentrations in the blood, potentially improving treatment outcomes for drugs with solubility challenges. Enzian is developing its manufacturing process and advancing its lead programs toward clinical validation.

Proprietary gastroretentive drug delivery platform utilizing 3D-printed, expandable fibrous dosage forms that swell in the stomach to provide sustained, constant drug release over ~24 hours.

Enzian competes in the gastroretentive drug delivery space against other technologies like floating systems, mucoadhesive systems, and high-density systems, many of which have faced development challenges. It also competes broadly with other controlled-release formulation technologies and must demonstrate superior performance and reliability to gain adoption.